Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.

Mansell, Kerry; Bhimji, Hishaam; Eurich, Dean; Mansell, Holly

Mansell, Kerry; Bhimji, Hishaam; Eurich, Dean; Mansell, Holly.

Afiliação

Mansell K; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 2Z4, Canada.
Bhimji H; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 2Z4, Canada.
Eurich D; School of Public Health, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Mansell H; College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 2Z4, Canada.

BMC Health Serv Res ; 19(1): 972, 2019 Dec 18.

Article em En | MEDLINE | ID: mdl-31849317

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: BMC Health Serv Res Assunto da revista: PESQUISA EM SERVICOS DE SAUDE Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google